Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib + Trametinib in East Asian BRAF V600+ Melanoma
NCT02083354Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in melanoma, sponsored by Novartis. Primary endpoint: Objective Response Rate up to 35 months. Started Mar 2014; status: completed.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02083354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083354.